Mel Mann, MBA, M.Ed @MelDMann

World’s Longest Living Gleevec & Targeted Kinase Inhibitor Survivor. 31 Year Terminal Cancer Survivor. Diagnosed as a Young Adult, Thriving as a Senior Survivor g.co/kgs/SgCVaQ5 Atlanta, GA Joined June 2009

Tweets

36K
Followers

478K
Following

247K
Likes

130K

OHSU Knight Cancer Institute @OHSUKnight

7 days ago

Transforming Cancer Care with Dr. Brian Druker Learn how Phil and Penny Knight’s historic $2B gift will help Dr. Druker transform the cancer care experience, starting right here in Oregon. 🗓️ June 27 ⌚️ 2:30-4 p.m. 📍 OHSU Auditorium Save your seat: bit.ly/4gonpJd

0 1 2 204 0

View Details

Memorial Sloan Kettering Cancer Center @MSKCancerCenter

7 days ago

Congratulations to MSK gastrointestinal medical oncologist @EileenMOReilly on being honored with the Hope Through Compassion Award from the @lustgartenfdn. The award recognizes her dedication to patients and her leadership in developing innovative clinical research for #pancreaticcancer. Watch to learn more about her approach to advancing pancreatic cancer research: bit.ly/3Qyo3cL

2 15 38 5K 0

View Details

Medidata @Medidata

7 days ago

We're excited to partner with Digital Medicine Society (DiMe) for a live panel discussion with speakers from @UR_Med and @VitalConnectInc on Cardiac Effort: a new digital biomarker that combines ECG (electrocardiogram) and accelerometry data from wearable sensors. Join us to learn how this helps researchers: ✅Reduce variability in 6MWT outcomes ✅Detect treatment effects with greater sensitivity ✅Enable remote assessments without compromising data quality ✅Modernize cardiovascular clinical trial endpoints, and more. Register here: mdso.io/xut #Medidata

0 1 3 234 0

View Details

OHSU Knight Cancer Institute @OHSUKnight

7 days ago

“Innovation has been limited over the past 2 decades, making these peer-reviewed data particularly important for patients with intermediate to high-risk localized prostate cancer.” Dr. Mark Garzotto on new #ProstateCancer research (@UrologyTimes): bit.ly/4osDzmT

0 1 1 204 0

View Details

Association of American Cancer Institutes @AACI_Cancer

7 days ago

Liliana Will, MPH, of @OHSUKnight, earned a 2nd place #CRI2026 abstract award for Mi Opción, an initiative that increased clinical trial participation through culturally tailored outreach and bilingual patient navigation. @OHSUNews

0 2 2 189 0

View Details

Blood Cancer United Advocacy @bcutd_advocacy

6 days ago

Our Advocacy Champion of the Year is Kristin Fuhrmann Simmons! Whether speaking to Congress or appearing on national news, Kristin makes complicated policy feel personal and urgent, always reminding us that these issues deeply affect real people and families. Thank you, Kristin!

0 1 5 165 0

View Details

National Cancer Institute @theNCI

6 days ago

Why are #KidneyCancer rates higher in some countries than others? Researchers used genomic "fingerprints" in tumors to uncover clues about possible environmental and biological factors that may influence kidney cancer risk around the world. go.nih.gov/hhpesK0

0 5 11 2K 3

View Details

Coping with Cancer @Coping_Cancer

6 days ago

“Gratitude, life perspective, and empathy are the gifts that came out of my ordeal. I wouldn’t trade my experience for anything. I wouldn’t wish it on anyone either.” @terryhealeyus shares his cancer journey in this new survivor story: copingmag.com/full-circle/

0 2 3 195 0

View Details

Mel Mann, MBA, M.Ed @MelDMann

a week ago

Cancer Today - Summer 2026 : Page 42 cancertoday-digital.org/cancertoday/li…

0 1 1 308 0

View Details

ACS Journal Cancer @JournalCancer

a week ago

🏥 When health care costs rise, some patients may forgo needed care. New research found higher out-of-pocket costs were associated with cost-related care avoidance among adults with and without a history of cancer. Read the full study: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert

0 9 11 932 0

View Details

Dana-Farber @DanaFarber

a week ago

We're excited to announce that we received a gift from Trustee Jennifer Perini to strengthen and expand our leadership in pediatric cancer survivorship and long-term quality of life. The gift establishes the Perini Family Chair in Survivorship and Lisa R. Diller, MD, has been selected as the inaugural incumbent. Please join us in congratulating Diller on this honor. This announcement is especially meaningful during Cancer Survivorship Month—for over 75 years, we’ve been working tirelessly to discover new treatments, develop new therapies, and set the standard of care for pediatric cancer in Boston and around the world.

0 2 17 1K 0

View Details

Dr. Patrick Hwu @PatrickHwuMD

a week ago

Spending time with our fellows @MoffittNews is always a highlight for me. Last week over breakfast, we had the chance to talk about their training, their goals and how we can continue supporting them as they grow as physicians, scientists and leaders. I always leave these conversations encouraged by their passion and commitment to making a difference for patients. @karenluMD @KarunNeupaneMD @umariqbalmed

0 2 22 4K 0

View Details

Mel Mann, MBA, M.Ed @MelDMann

a week ago

How a pill approved 25 years ago transformed cancer treatment vpm.org/npr-news/npr-n…

0 0 6 366 0

View Details

Mel Mann, MBA, M.Ed @MelDMann

a week ago

How a pill approved 25 years ago transformed cancer treatment - OPB opb.org/article/2026/0…

0 0 1 301 0

View Details

ABC News @ABC

a week ago

The U.S. Food and Drug Administration has elevated a recall of Alfredo sauce distributed in 41 states to its most serious classification after they say a supplier flagged an ingredient for possible Salmonella contamination. Read more: abcnews.link/HTe1Nk6

15 76 124 43K 16

View Details

ACRP - Assoc. of Clinical Research Profession @ACRPDC

2 weeks ago

In today’s evolving clinical research environment, staying competitive means aligning your expertise with the latest industry standards. Apply for ACRP Certification at reduced rates through July 15. The testing cycle runs from July 15 – October 15 > bit.ly/4cG02Wl

0 1 3 238 0

View Details

ASH @ASH_hematology

2 weeks ago

ASH has announced new names for several honorific awards recognizing pioneers whose work transformed #hematology through research, mentorship, equity, and clinical care. Learn more in ASH Clinical News: ow.ly/7rxu50Z8Lv4 #ASHAwards @ASHClinicalNews

0 4 16 2K 1

View Details

Dr. Patrick Hwu @PatrickHwuMD

2 weeks ago

🧬 #ScienceSaturday ❓ Why does immunotherapy work so well for some cancers, but often fail in #glioblastoma, one of the most aggressive brain cancers? ➡️ A new study in @NatureCancer suggests the answer may depend less on how many DNA mutations a tumor has, and more on the tumor’s “cell state,” or what the cancer cells are actively doing. ➡️ Researchers studied 181 glioblastoma samples from patients treated with immune checkpoint blockade, a type of immunotherapy designed to help T cells recognize and attack cancer. ➡️ They found that glioblastomas in a mesenchymal, or MES, state were linked to better survival after immunotherapy. These tumors appeared more “immune-visible,” with higher levels of HLA class I, a signal that helps T cells recognize abnormal cells, and more T cell infiltration. ➡️ Surprisingly, #tumor mutational burden, a marker often used to predict immunotherapy response in other cancers, did not predict better outcomes in this glioblastoma group. ➡️ The study also revealed a possible escape route: after #immunotherapy, some tumors shifted away from the MES state toward non-MES states, which may make them less recognizable to the immune system and more resistant to treatment. 🧠 Why this matters: Glioblastoma has been extremely difficult to treat, and checkpoint immunotherapy has mostly been disappointing in this disease. This study suggests that future trials may need to look at a tumor’s RNA “activity pattern,” not just its #DNA mutations, to identify patients who may be more likely to benefit. ✨ Big takeaway: In glioblastoma, the tumor’s current “state of mind” may help predict whether immunotherapy can see it, attack it, and make a difference. Read more here: nature.com/articles/s4301… @Nature @DanaFarber @Harvard @Harvardmed @MassGenBrigham @broadinstitute @IBMResearch @DanaFarberNews @EAChiocca @JackYGhannam

4 32 103 12K 56

View Details

AA&MDSIF @aamdsif

2 weeks ago

New Investigator Research Grants Available! LOIs invited for Aplastic Anemia, MDS, or PNH - $80,000/2-year grant from AAMDSIF Deadline for LOI: June 30, 2026 Details and contact: aamds.org/fund-your-rese…